Avid Bioservices Inc (CDMO)

[entdoc]

k_t, thanks for asking. 2-3 years ago I wrote here I agreed with one of the "negative" posters that [the current iteration] of Bavi might not be approved, and after the India trials (a couple years ago? seems like eons)I wrote here that approval was probably going to be a statistical "squeaker", and I'm still in that corner. The problem is that the FDA is not going to get excited about a squeaker, especially when Avastin indications are actively shrinking, rather than expanding. So questions about the control arm of the trial, and matching or barely exceeding Avastin, simply do not capture many people's imagination. We learned something of value from a trial on patients with very serious disease. That's it.Move forward with the program. Definitely. And...be grateful to those patients with such severe illness for their bravery in volunteering to help move closer to a cure. Does a continued presence here, or in PPHM stock, makes sense? I think so. The company's intellectual properties are remarkable, and their progress to date spectacular. There is increasing focus and interest in PPHM. Last week was definitely not a great leap forward, but not to get all bogged down in it.
What's next?!